Nano drugs delivery system: A novel promise for the treatment of atrial fibrillation

Abstract

Atrial fibrillation (AF) is one of the most common sustained tachyarrhythmias worldwide, and its prevalence is positively correlated with aging. AF not only significantly reduces the quality of life of patients but also causes a series of complications, such as thromboembolism, stroke, and heart failure, increases the average number of hospitalizations of patients, and places a huge economic burden on patients and society. Traditional drug therapy and ablation have unsatisfactory success rates, high recurrence rates, and the risk of serious complications. Surgical treatment is highly traumatic. The nano drug delivery system has unique physical and chemical properties, and in the application of AF treatment, whether it is used to assist in enhancing the ablation effect or for targeted therapy, it provides a safer, more effective and more economical treatment strategy.

Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives

“…These systems offer improved therapeutic outcomes, reduced recurrence rates, and enhanced safety compared to traditional drug therapy and ablation. The targeted delivery capabilities of nanosystems hold promise for more effective and economical treatment strategies, addressing the clinical challenges associated with AF management and improving patient outcomes [ 34 ].…”

“…Nanotechnology provides targeted drug-delivery systems for the ablation of abnormal heart muscle cells, management of arrhythmias, and post-operative atrial fibrillation [ 31 , 32 , 33 , 34 , 35 ]. Sirolimus nanoparticles have been investigated for their potential in reducing inflammation response and restenosis rates in lower extremity arteries after balloon injury [ 35 , 36 ].…”